Venus Concept announces the first treatment of a patient within the framework of a study


TORONTO, April 25, 2022 (GLOBE NEWSWIRE) — Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global leader in medical aesthetic technology, today announced that the first patient was treated in a US Investigational Device Exemption (IDE) clinical study evaluating the safety and efficacy of the Company’s next-generation Aime™ robotic technology for the treatment of moderate to severe facial wrinkles. Aime is a robotic platform designed to provide micro-coring for medical aesthetic applications.

“The introduction of robotics is one of the most exciting breakthroughs in aesthetic medicine,” said lead researcher Steven Dayan, MD. must be accurate, patient and provider friendly, and affordable, while providing reliable aesthetic improvement. However, recent advances in technology and thinking are leading to new designs and treatments.

Dr. Dayan continued, “We are delighted to have successfully completed the patient’s initial treatment with the Aime robotic platform for this important clinical study. Aime represents an innovative approach to aesthetic procedures, with the potential to provide clinicians with consistent, predictable treatment delivery and improved visualization. Aime could very well differentiate adoptive clinicians as the use of robotic technology emerges in aesthetic procedures.

The study is a multicenter, prospective clinical study evaluating the safety and efficacy of mechanical coring for improving the appearance of facial wrinkles. It will be conducted at four research centers in the United States and will include up to 70 subjects between the ages of 22 and 75. The study will assess subjects’ progress after two cheek treatments, delivered 30 days apart. The primary endpoint will be the proportion of correctly identified sets of photographs from baseline and day 120, as assessed by at least 3 blinded independent raters.

About Venus Concept

Venus Concept is an innovative global leader in medical aesthetic technologies with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 18 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and its well-established direct global markets. Venus Concept’s product portfolio includes aesthetic device platforms including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Glow, Venus Bliss, Venus BlissMAX, Venus Epileve and Venus Viva MD. Venus Concept’s hair restoration systems include NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during an FUE process and the ARTAS® and ARTAS iX® robotic hair restoration systems, which harvest the units follicles directly from the scalp and create recipient implantation sites. using proprietary algorithms. Venus Concept has been backed by leading healthcare growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, Aperture Venture Partners and Masters Special Situations.

Caution Regarding Forward-Looking Statements

This communication contains contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained herein that are not historical facts may be deemed to be forward-looking statements. In some cases, you can identify these statements by words such as “anticipates”, “believes”, “plans”, “expects”, “plans”, “future”, “intends”, ” may”, “should”, “could”, “estimate”, “predict”, “potential”, “continue”, “direction” and other similar expressions that are predictions or indicate future events and future trends. These forward-looking statements include, but are not limited to, statements about our financial performance; growth in demand for our systems and other products; and general economic conditions, including the global economic impact of COVID-19, and involve risks and uncertainties that could cause actual results to differ materially from those set forth in the statements. These forward-looking statements are based on current expectations, estimates, forecasts and projections regarding our business and the industry in which the company operates and on management’s beliefs and assumptions and are not guarantees of future performance or developments and involve known and unknown risks, uncertainties, and other factors that are in some cases beyond our control. Accordingly, some or all of our forward-looking statements contained in this communication may prove to be inaccurate. Factors that could materially affect our business operations and our financial performance and condition include, but are not limited to, the risks and uncertainties described in Part II, Item 1A – “Risk Factors” in our quarterly reports on Form 10-Q and Part I, Item 1A. —”Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2021. You are urged to carefully consider these factors when evaluating forward-looking statements and cautioned not to rely unduly to forward-looking statements. – look at the statements. Forward-looking statements are based on information available to us as of the date of this communication. Except as required by law, the Company does not intend to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise.


Comments are closed.